Versor Investments LP reduced its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 43.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,367 shares of the biotechnology company's stock after selling 2,634 shares during the period. Versor Investments LP's holdings in Repligen were worth $485,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. UMB Bank n.a. grew its position in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of Repligen during the third quarter worth about $13,202,000. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after purchasing an additional 36,773 shares during the last quarter. Geneva Capital Management LLC boosted its position in shares of Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after purchasing an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC grew its stake in Repligen by 14.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company's stock worth $41,019,000 after buying an additional 35,115 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on RGEN. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. StockNews.com cut shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Finally, Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $181.00.
Read Our Latest Stock Report on RGEN
Repligen Price Performance
Shares of Repligen stock traded up $2.86 during trading on Wednesday, reaching $157.67. The company's stock had a trading volume of 654,974 shares, compared to its average volume of 611,956. The business has a 50 day moving average price of $156.74 and a 200-day moving average price of $148.54. The company has a market capitalization of $8.83 billion, a P/E ratio of -309.16, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $203.13.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
